囊性纤维化晚期肺病患者启用Elexacaftor-Tezacaftor-Ivacaftor后快速改善
该研究为法国前瞻性观察性研究,纳入2019年12月至2020年8月启动Elexacaftor-Tezacaftor-Ivacaftor、年龄≥12岁且ppFEV1<40的囊性纤维化患者245例,中位ppFEV1为29(24-34)。治疗1个月和3个月时评估,ppFEV1平均绝对增加+15.1(95%CI +13.8至+16.4;P<0.0001),体重平均增加+4.2 kg(95%CI +3.9至+4.6;P<0.0001)。需要长期氧疗、无创通气、肠内管饲的患者数分别减少50%、30%、50%(P<0.01)。启动治疗时16例在移植等待名单、37例正在接受移植评估,最终仅2例接受移植、1例死亡;至2020年9月仅5例仍在移植路径上。与之前2年相比,2020年囊性纤维化患者肺移植数减少两倍,而未移植死亡数保持稳定。
要点
- 在ppFEV1<40的囊性纤维化患者中,启用Elexacaftor-Tezacaftor-Ivacaftor后ppFEV1平均绝对增加+15.1(95%CI +13.8至+16.4;P<0.0001)。
- 体重平均增加+4.2 kg(95%CI +3.9至+4.6;P<0.0001)。
- 需要长期氧疗、无创通气、肠内管饲的患者数分别减少50%、30%、50%(P<0.01)。
- 启动治疗时16例在移植等待名单、37例正在移植评估,最终仅2例接受移植、1例死亡;至2020年9月仅5例仍在移植路径上。
- 与之前2年相比,2020年囊性纤维化患者肺移植数减少两倍,而未移植死亡数保持稳定。
适用人群与场景
- 年龄≥12岁、ppFEV1<40的囊性纤维化患者,于2019年12月至2020年8月在法国启动Elexacaftor-Tezacaftor-Ivacaftor治疗。
研究设计与关键结果
- 前瞻性观察性研究纳入245例患者,中位ppFEV1=29(24-34);在启动治疗时、1个月和3个月收集临床特征,至2020年9月评估安全性和有效性。
- ppFEV1平均绝对增加+15.1(95%CI +13.8至+16.4;P<0.0001),体重平均增加+4.2 kg(95%CI +3.9至+4.6;P<0.0001)。
- 需要长期氧疗、无创通气、肠内管饲的患者数分别减少50%、30%、50%(P<0.01)。
- 启动治疗时16例在移植等待名单、37例正在移植评估,最终仅2例接受移植、1例死亡;至2020年9月仅5例仍在移植路径上。
- 与之前2年相比,2020年囊性纤维化患者肺移植数减少两倍,而未移植死亡数保持稳定。
证据类型、等级与局限
- 前瞻性观察性研究;原文未报告局限性。
对床旁实践的改变
- 作者认为,在晚期肺病患者中,Elexacaftor-Tezacaftor-Ivacaftor与快速临床改善相关,常导致肺移植指征被暂停。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Elexacaftor-tezacaftor-ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator combination, developed for patients with CF with at least one Phe508del mutation. Objectives: To evaluate the effects of elexacaftor-tezacaftor- ivacaftor in patients with CF and advanced respiratory disease. Methods: A prospective observational study, including all patients aged ⩾12 years and with a percent-predicted FEV1 (ppFEV1) <40 who initiated elexacaftor-tezacaftor-ivacaftor from December 2019 to August 2020 in France was conducted. Clinical characteristics were collected at initiation and at 1 and 3 months. Safety and effectiveness were evaluated by September 2020. National-level transplantation and mortality figures for 2020 were obtained from the French CF and transplant centers and registries. Measurements and Main Results: Elexacaftor-tezacaftor- ivacaftor was initiated in 245 patients with a median (interquartile range) ppFEV1 = 29 (24-34). The mean (95% confidence interval) absolute increase in the ppFEV1 was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence interval) in weight was +4.2 kg (+3.9 to +4.6; P < 0.0001). The number of patients requiring long-term oxygen, noninvasive ventilation, and/or enteral tube feeding decreased by 50%, 30%, and 50%, respectively (P < 0.01). Although 16 patients were on the transplant waiting list and 37 were undergoing transplantation evaluation at treatment initiation, only 2 received a transplant, and 1 died. By September 2020, only five patients were still on the transplantation path. Compared with the previous 2 years, a twofold decrease in the number of lung transplantations in patients with CF was observed in 2020, whereas the number of deaths without transplantation remained stable. Conclusions: In patients with advanced disease, elexacaftor-tezacaftor-ivacaftor is associated with rapid clinical improvement, often leading to the indication for lung transplantation being suspended.
参考来源
- Burgel PR, Durieu I, Chiron R, et al. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am J Respir Crit Care Med. 2021. PMID: 33600738. doi:10.1164/rccm.202011-4153OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。